- Home
- REVB vs SXTP Comparison
REVB vs SXTP Comparison
Compare REVB & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SXTP
- Stock Information
- Founded
- REVB 2020
- SXTP 2010
- Country
- REVB United States
- SXTP United States
- Employees
- REVB N/A
- SXTP N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- SXTP Health Care
- Exchange
- REVB Nasdaq
- SXTP Nasdaq
- Market Cap
- REVB 1.4M
- SXTP 1.6M
- IPO Year
- REVB N/A
- SXTP 2023
- Fundamental
- Price
- REVB $0.34
- SXTP $1.38
- Analyst Decision
- REVB
- SXTP Hold
- Analyst Count
- REVB 0
- SXTP 1
- Target Price
- REVB N/A
- SXTP N/A
- AVG Volume (30 Days)
- REVB 1.7M
- SXTP 712.1K
- Earning Date
- REVB 11-08-2024
- SXTP 11-14-2024
- Dividend Yield
- REVB N/A
- SXTP N/A
- EPS Growth
- REVB N/A
- SXTP N/A
- EPS
- REVB N/A
- SXTP N/A
- Revenue
- REVB N/A
- SXTP $462,612.00
- Revenue This Year
- REVB N/A
- SXTP $267.05
- Revenue Next Year
- REVB N/A
- SXTP $181.82
- P/E Ratio
- REVB N/A
- SXTP N/A
- Revenue Growth
- REVB N/A
- SXTP 128.99
- 52 Week Low
- REVB $0.32
- SXTP $0.70
- 52 Week High
- REVB $25.26
- SXTP $18.36
- Technical
- Relative Strength Index (RSI)
- REVB 27.29
- SXTP 52.58
- Support Level
- REVB $0.32
- SXTP $1.35
- Resistance Level
- REVB $0.47
- SXTP $1.74
- Average True Range (ATR)
- REVB 0.08
- SXTP 0.28
- MACD
- REVB -0.02
- SXTP 0.01
- Stochastic Oscillator
- REVB 3.40
- SXTP 26.00
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.